AIA Group Ltd Sells 5,369 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

AIA Group Ltd cut its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 19.0% in the 4th quarter, HoldingsChannel reports. The firm owned 22,848 shares of the biopharmaceutical company’s stock after selling 5,369 shares during the quarter. AIA Group Ltd’s holdings in Alnylam Pharmaceuticals were worth $5,376,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Quantbot Technologies LP raised its position in Alnylam Pharmaceuticals by 1,754.5% in the third quarter. Quantbot Technologies LP now owns 204 shares of the biopharmaceutical company’s stock worth $56,000 after acquiring an additional 193 shares during the period. Bridgewater Associates LP bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth approximately $551,000. Captrust Financial Advisors lifted its stake in Alnylam Pharmaceuticals by 34.4% in the third quarter. Captrust Financial Advisors now owns 4,833 shares of the biopharmaceutical company’s stock valued at $1,329,000 after purchasing an additional 1,237 shares during the last quarter. True Wealth Design LLC grew its holdings in Alnylam Pharmaceuticals by 15,300.0% during the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 153 shares during the period. Finally, Erste Asset Management GmbH purchased a new stake in Alnylam Pharmaceuticals in the third quarter worth $4,539,000. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock opened at $268.46 on Monday. The stock has a market capitalization of $34.92 billion, a price-to-earnings ratio of -123.71 and a beta of 0.39. The company has a fifty day moving average of $259.86 and a 200-day moving average of $260.52. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently commented on ALNY. Sanford C. Bernstein dropped their price target on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. Morgan Stanley increased their target price on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. HC Wainwright upped their price target on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a “buy” rating in a research note on Monday, February 24th. Finally, JPMorgan Chase & Co. upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $280.00 to $328.00 in a research note on Monday, March 24th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $312.30.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total value of $362,246.40. Following the sale, the executive vice president now owns 12,881 shares of the company’s stock, valued at $3,240,344.36. This trade represents a 10.06 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Phillip A. Sharp sold 11,250 shares of the company’s stock in a transaction dated Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total transaction of $3,093,750.00. The disclosure for this sale can be found here. Insiders have sold a total of 71,234 shares of company stock worth $19,958,097 in the last ninety days. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.